V. Kukreti

S. Trudel, D. Reece, V. Kukreti, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume

R. Kridel, R. Tsang, Wei Xu, 2021, American journal of hematology.

Predicting the Risks of Aggressive-Intent Chemotherapy Toxicity in Older Patients With Lymphoma: A Prospective Observational Pilot Study.

A. Prica, V. Kukreti, J. Kuruvilla, 2022, Clinical lymphoma, myeloma & leukemia.

Feasibility randomised controlled trial of remote symptom chemotherapy toxicity monitoring using the Canadian adapted Advanced Symptom Management System (ASyMS-Can): a study protocol

P. Morita, Geoffrey Liu, V. Kukreti, 2020, BMJ Open.

Spontaneous remission in a patient with t(4;14) translocation multiple myeloma.

J. Keats, G. Ahmann, R. Fonseca, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group

V. D’Agati, A. Dispenzieri, R. Kyle, 2018, Nature Reviews Nephrology.

Publisher Correction: The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group

V. D’Agati, A. Dispenzieri, R. Kyle, 2018, Nature Reviews Nephrology.

Rapidity and quality of response to steroid-based induction therapy, without the addition of novel agents, does not affect post transplant outcomes in multiple myeloma.

S. Trudel, D. Reece, W. Xu, 2013, Clinical lymphoma, myeloma & leukemia.

Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia

S. Trudel, D. Reece, V. Kukreti, 2015, Leukemia & lymphoma.

Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: experience of a single institution

S. Trudel, D. Reece, V. Kukreti, 2014, British journal of haematology.

Two distinct syndromes of lymphoma associated AL amyloidosis: A case series and review of the literature

D. Reece, V. Kukreti, M. Crump, 2010, American journal of hematology.

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.

Michael L. Wang, M. Dimopoulos, A. Palumbo, 2016, Blood.

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2013, Leukemia.

Evaluation of 2009 pandemic H1N1 influenza vaccination in adults with lymphoid malignancies receiving chemotherapy or following autologous stem cell transplant

W. Xu, V. Kukreti, M. Crump, 2013, Leukemia & lymphoma.

Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.

P. L. Bergsagel, R. Fonseca, S. Trudel, 2010, Blood.

Single‐center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation

S. Trudel, M. Maganti, D. Reece, 2018, Clinical lymphoma, myeloma & leukemia.

Implementation and Impact of Choosing Wisely Recommendations in Oncology.

V. Kukreti, M. Krzyzanowska, M. Powis, 2022, JCO oncology practice.

Bridging efforts to longitudinally improve and evaluate VEnous thromboembolism prophylaxis uptake in hospitalized cancer patients through Interprofessional Teamwork (BELIEVE IT): a study by Princess Margaret Cancer Centre.

E. Atenafu, V. Kukreti, M. Krzyzanowska, 2014, Thrombosis research.

Bridging efforts to longitudinally improve and evaluate venous thromboembolism prophylaxis uptake in hospitalized cancer patients through interprofessional teamwork (BELIEVE IT): A study by Princess Margaret Cancer Centre.

V. Kukreti, M. Krzyzanowska, Triyu Vather, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Limited-stage mantle cell lymphoma: treatment outcomes at the Princess Margaret Hospital

R. Tsang, M. Gospodarowicz, A. Sun, 2013, Leukemia & lymphoma.

Monoclonal and Oligoclonal Bands After Single Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: Impact On Overall Survival and Progression-Free Survival

S. Trudel, V. Kukreti, R. Tiedemann, 2012 .

Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab

R. Tsang, T. Panzarella, V. Kukreti, 2015, Leukemia & lymphoma.

A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191

L. Seymour, T. Reiman, D. Reece, 2016, Leukemia & lymphoma.

Long‐term follow‐up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia

P. L. Bergsagel, S. Trudel, V. Kukreti, 2014, British journal of haematology.

Rituximab-Induced Coronary Vasospasm

V. Kukreti, Linda Lee, 2012, Case reports in hematology.

Pathology the Gold Standard – A Retrospective Analysis of Discordant “Second-Opinion” Lymphoma Pathology and Its Impact on Patient Care.

E. Etchells, V. Kukreti, M. Crump, 2006 .

Long-term survival in two patients with hepatosplenic T cell lymphoma treated with interferon-alpha

M. Humphreys, V. Kukreti, I. Quirt, 2008, Leukemia & lymphoma.

A Case of Rapid Deterioration with Marked Hypergammaglobulinemia.

V. Kulasingam, V. Kukreti, F. Leung, 2020, Clinical chemistry.

Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma.

S. Trudel, D. Reece, E. Atenafu, 2016, Clinical lymphoma, myeloma & leukemia.

The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database

D. Reece, E. Atenafu, V. Kukreti, 2020, Haematologica.

Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma

S. Trudel, D. Reece, V. Kukreti, 2013, Leukemia & lymphoma.

Selinexor Demonstrates Marked Synergy with Dexamethasone (Sel-Dex) in Preclinical Models and in Patients with Heavily Pretreated Refractory Multiple Myeloma (MM)

A. Azmi, C. Hofmeister, D. Siegel, 2014 .

Kinetics of response to first‐ and second‐line therapies in multiple myeloma: Assessment by both M‐spikes and light chains

S. Trudel, D. Reece, Xuan Li, 2021, European journal of haematology.

A phase 2 study of single-agent carﬁlzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012 .

The impact of lenalidomide maintenance on second‐line chemotherapy in transplant eligible patients with multiple myeloma

D. Reece, E. Atenafu, V. Kukreti, 2021, European journal of haematology.

CyBorD induction therapy in clinical practice

S. Trudel, D. Reece, V. Kukreti, 2015, Bone Marrow Transplantation.

Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents

S. Trudel, D. Reece, V. Kukreti, 2015, Bone Marrow Transplantation.

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012, Blood.

Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis

S. Jagannath, A. Jakubowiak, S. Lonial, 2011 .

Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .

Pooled Safety Analysis From Phase (Ph) 1 and 2 Studies of Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (MM)

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .

The Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Demonstrates Broad and Durable Clinical Activity in Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL)

J. Byrd, I. Flinn, R. Garzon, 2014 .

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012, Blood.

Oligoclonal and monoclonal bands after single autologous stem cell transplant in patients with multiple myeloma: impact on overall survival and progression-free survival

S. Trudel, D. Reece, V. Kukreti, 2014, Leukemia & lymphoma.

Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.

P. L. Bergsagel, S. Trudel, S. Gibson, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated Results of Bortezomib-Naïve Patients in PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM).

A. Jakubowiak, R. Vij, A. Belch, 2009 .

Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents

S. Trudel, R. Tsang, D. Reece, 2013, British journal of haematology.

Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study.

G. Pond, K. Pritchard, V. Kukreti, 2016, Clinical lymphoma, myeloma & leukemia.

Chemotherapy with stem cell transplantation is more effective than immunotherapy in sporadic late onset nemaline myopathy with monoclonal gammopathy

R. Kotchetkov, V. Kukreti, A. Dyszkiewicz-Korpanty, 2018, Bone Marrow Transplantation.

Phase I‐II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma

S. Trudel, D. Reece, E. Atenafu, 2015, British journal of haematology.

Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma.

S. Trudel, D. Reece, W. Xu, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Post Salvage Therapy Autologous Transplant for Relapsed Myeloma, Ongoing Relevance within Modern Treatment Paradigms?

S. Trudel, D. Reece, E. Atenafu, 2022, Clinical lymphoma, myeloma & leukemia.

Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival.

S. Trudel, D. Reece, V. Kukreti, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.

Ryan D. Morin, Lauren C. Chong, C. Greenwood, 2016, Blood.

Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Michael L. Wang, M. Dimopoulos, A. Palumbo, 2015, The New England journal of medicine.

Validation of the RHL30 digital gene expression assay as a prognostic biomarker for relapsed Hodgkin lymphoma

D. Scott, R. Kridel, C. Steidl, 2020, British journal of haematology.

Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12.

Bingshu E. Chen, M. Federico, V. Kukreti, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.

Huyuan Yang, A. Hui, D. Seldin, 2017, Blood.

Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.

D. Esseltine, D. Reece, V. Kukreti, 2014, Blood.

A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end‐stage renal disease requiring haemodialysis

Huyuan Yang, A. Hui, K. Venkatakrishnan, 2016, British journal of haematology.

Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL)

A. Hui, A. Dispenzieri, V. Kukreti, 2014 .

Absolute lymphocyte count as predictor of overall survival for patients with multiple myeloma treated with single autologous stem cell transplant

S. Trudel, D. Reece, V. Kukreti, 2015, Leukemia & lymphoma.

Treatment outcomes for older patients with relapsed/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: a subgroup analysis from the phase III CCTG LY.12 trial

K. Davison, V. Kukreti, M. Crump, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Cyclophosphamide and prednisone induction followed by cyclophosphamide mobilization effectively decreases the incidence of engraftment syndrome in patients with POEMS syndrome who undergo stem cell transplantation

S. Trudel, D. Reece, V. Kukreti, 2011, American journal of hematology.

High-Dose Melphalan for AL Amyloidosis: The Importance of Case Selection to Improve Clinical Outcomes

S. Trudel, D. Reece, V. Kukreti, 2010 .

Clinical significance of clonal hematopoiesis in the setting of autologous stem cell transplantation for lymphoma

R. Kridel, J. Dick, M. Minden, 2021, American journal of hematology.

Tale of two lymphomas: peripheral T-cell lymphoma after allogeneic stem-cell transplantation for marginal zone lymphoma.

J. Lipton, V. Kukreti, D. Bailey, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Five hematologic tests and treatments to question.

W. Wood, M. Pasquini, S. O’Brien, 2014, Blood.

Light Chain Deposition Disease: Impact of Stem Cell Tranplant on Hematological Response Achievement.

S. Trudel, D. Reece, V. Kukreti, 2010 .

Autologous stem cell transplant for light chain deposition disease: Incorporating bortezomib to the induction therapy

S. Trudel, D. Reece, V. Kukreti, 2012, American journal of hematology.

Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure

S. Trudel, V. Kukreti, R. Tiedemann, 2015, Bone Marrow Transplantation.

Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid®) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma.

S. Trudel, D. Reece, V. Kukreti, 2009 .

D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma

S. Trudel, T. Panzarella, D. Reece, 2013, British journal of haematology.

Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone (KPd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): A Multiple Myeloma Research Consortium multicenter study.

K. Griffith, A. Jakubowiak, T. Zimmerman, 2016 .

An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment – validation of official dosing guidelines

S. Trudel, D. Reece, A. Prica, 2020, Leukemia & lymphoma.

Clinical utility of interim CT scans in patients receiving chemoimmuntherapy for first line treatment of follicular lymphoma

R. Kridel, A. Prica, V. Kukreti, 2021, Leukemia & lymphoma.

A Phase II Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL).

S. Trudel, V. Kukreti, W. Xu, 2007 .

MLN9708, a Novel, Investigational Oral Proteasome Inhibitor, in Patients with Relapsed or Refractory Light-Chain Amyloidosis (AL): Results of a Phase 1 Study

A. Hui, A. Dispenzieri, V. Kukreti, 2012 .

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012, Blood.

Cyclophosphamide, bortezomib and dexamethasone (CyBorD) induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial

P. L. Bergsagel, R. Fonseca, S. Trudel, 2009, Leukemia.

Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation

R. Kridel, S. Trudel, D. Reece, 2019, Blood.

Syngeneic transplants for multiple myeloma – a single center experience and review of the literature

S. Trudel, D. Reece, A. Prica, 2020, Leukemia & lymphoma.

Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras

S. Trudel, D. Reece, E. Atenafu, 2019, Bone Marrow Transplantation.

Identifying existing Choosing Wisely recommendations of high relevance and importance to hematology

W. Wood, M. Pasquini, S. O’Brien, 2016, American journal of hematology.

Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: Final Results of the Randomized Phase III NCIC CTG Study LY12

Bingshu E. Chen, M. Federico, V. Kukreti, 2012 .

Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients

F. Zhan, S. Jagannath, A. Jakubowiak, 2011, European journal of haematology.

Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone

S. Trudel, D. Reece, E. Atenafu, 2015, Leukemia & lymphoma.

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carﬁlzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012 .

Supermobilizers with High CD34 + Cell Collection for Autologous Transplant and Impact on Survival Outcomes in Multiple Myeloma

S. Trudel, D. Reece, K. Lajkosz, 2021, Blood.

A Phase II Trial Comparison of Once Versus Twice Weekly Bortezomib in CYBORD Chemotherapy for Newly Diagnosed Myeloma: Identical High Response Rates and Less Toxicity.

P. L. Bergsagel, R. Fonseca, S. Trudel, 2009 .

Five hematologic tests and treatments to question.

W. Wood, M. Pasquini, S. O’Brien, 2014, Hematology. American Society of Hematology. Education Program.

Tolerability and Efficacy of Post Transplant Lenalidomide Maintenance Therapy in Multiple Myeloma: A Real World Single Centre Experience

S. Trudel, D. Reece, A. Prica, 2017 .

Pattern of First Relapse in Multiple Myeloma (MM) Patients (Pts) after a Cybord Induction Regimen and Autologous Stem Cell Transplantation (ASCT): Impact of Maintenance Therapy in the Real-World Setting

S. Trudel, D. Reece, E. Atenafu, 2016 .

Treatment and outcomes for primary cutaneous extramedullary plasmacytoma: a case series.

A. Sun, V. Kukreti, D. Tsang, 2016, Current oncology.

Lenalidomide Desensitization in Systemic Light-Chain Amyloidosis With Multi-Organ Involvement

V. Kukreti, J. Seki, N. Sakurai, 2015, Journal of clinical medicine research.

Phase I Trial of Pomalidomide, Bortezomib, and Dexamethasone As Frontline Treatment of AL Amyloidosis

S. Tuchman, V. Kukreti, J. Zonder, 2017 .

Feasibility and Effectiveness of Self-Management Education and Coaching on Patient Activation for Managing Cancer Treatment Toxicities.

G. Pond, V. Kukreti, D. Bryant-Lukosius, 2023, Journal of the National Comprehensive Cancer Network : JNCCN.

Improving the Safety and Quality of Systemic Treatment Regimens in Computerized Prescriber Order Entry Systems.

V. Kukreti, Kathy Vu, Andrea Crespo, 2018, Journal of Oncology Practice.

Clinical characteristics and early treatment outcomes of follicular lymphoma in young adults

M. Maganti, R. Tsang, M. Gospodarowicz, 2015, British journal of haematology.

Frequency and Clinical Importance of Pathological Discordance in Lymphoma

V. Kukreti, 2010 .

The ASH Choosing Wisely®campaign: five hematologic tests and treatments to question.

M. Pasquini, S. O’Brien, V. Kukreti, 2013, Hematology. American Society of Hematology. Education Program.

The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question.

Kenneth R Carson, Alice Ma, Ravindra Sarode, 2013, Blood.

Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naïve patients

M. Maganti, A. Prica, V. Kukreti, 2019, Leukemia & lymphoma.

Effectiveness and tolerability of first-line autologous stem cell transplant and maintenance rituximab for mantle cell lymphoma

R. Tsang, V. Kukreti, M. Crump, 2018, Bone Marrow Transplantation.

Impact of a Training Program on Oncology Nurses’ Confidence in the Provision of Self-Management Support and 5As Behavioral Counseling Skills

V. Kukreti, D. Bryant-Lukosius, D. Howell, 2023, Cancers.

Tolerability of Velcade (Bortezomib) subcutaneous administration using a maximum volume of 3 mL per injection site

S. Trudel, D. Reece, V. Kukreti, 2015, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Development and Validation of a Score to Predict Acute Care Use After Initiation of Systemic Therapy for Cancer

R. Moineddin, V. Kukreti, R. Grant, 2019, JAMA network open.

PX-171-004, a multicenter phase II study of carfilzomib (CFZ) in patients with relapsed myeloma: An efficacy update.

S. Jagannath, D. Siegel, R. Vij, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ambulatory Toxicity Management (AToM) Pilot: results of a pilot study of a pro-active, telephone-based intervention to improve toxicity management during chemotherapy for breast cancer

Kelvin K. W. Chan, C. Atzema, V. Kukreti, 2019, Pilot and Feasibility Studies.

Cavitating Mesenteric Lymph Node Syndrome and Enteropathy-Associated T Cell Lymphoma as First Manifestation of Celiac Disease

R. Kotchetkov, V. Kukreti, 2015 .

PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort.

S. Jagannath, A. Jakubowiak, R. Vij, 2009 .

Initial Results of PX-171-004, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM)

Michael L. Wang, S. Jagannath, D. Siegel, 2008 .

Lenalidomide (Revlimid®) +/− Corticosteroids in Elderly Patients with Relapsed/Refractory Multiple Myeloma.

S. Trudel, D. Reece, V. Kukreti, 2006 .

Use of Lenalidomide (Revlimid® +/− Corticosteroids in Relapsed/Refractory Multiple Myeloma Patients with Elevated Baseline Serum Creatinine Levels.

S. Trudel, D. Reece, V. Kukreti, 2006 .

Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2011 .

Long‐term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma

R. Fonseca, S. Trudel, D. Reece, 2014, British journal of haematology.

Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391)

Michael L. Wang, M. Dimopoulos, A. Palumbo, 2015 .

Implementation of medication reconciliation in outpatient cancer care

V. Kukreti, M. Krzyzanowska, Hemangi Dave, 2023, BMJ open quality.

Implementation and impact of Choosing Wisely recommendations in oncology: A scoping review.

V. Kukreti, M. Krzyzanowska, M. Powis, 2021, Journal of Clinical Oncology.

Five biopsies, one diagnosis: challenges in idiopathic multicentric Castleman disease

V. Kukreti, A. Sakhdari, J. Semenchuk, 2020, BMJ Case Reports.

treatments to question campaign : five hematologic tests and ® The ASH Choosing Wisely

M. Pasquini, S. O’Brien, V. Kukreti, 2013 .

Long-Term Follow-up of a Phase 2 Study of Single Agent Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)

P. L. Bergsagel, S. Trudel, V. Kukreti, 2012 .

Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM).

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .

Incidence and Predictors of Bleomycin Pulmonary Toxicity in Hodgkin Lymphoma (HL) Patients Treated with Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD),

R. Tsang, E. Atenafu, V. Kukreti, 2011 .

A Retrospective Study on the Incidence of Rituximab-Related Interstitial Pneumonitis In Patients Undergoing Immunochemotherapy for Non-Hodgkin Lymphoma

R. Tsang, V. Kukreti, M. Crump, 2010 .

A Web-Based Cancer Self-Management Program (I-Can Manage) Targeting Treatment Toxicities and Health Behaviors: Human-Centered Co-design Approach and Cognitive Think-Aloud Usability Testing

V. Kukreti, S. Moradian, M. Krzyzanowska, 2022, JMIR cancer.

Primary Marginal Zone Lymphoma of the Subcutis Associated With Panniculitis and Fat Necrosis.

J. Delabie, V. Kukreti, C. Wei, 2015, American journal of clinical pathology.

Systemic Treatment Safety Symposium 2014: Oral Chemotherapy

V. Kukreti, M. Krzyzanowska, E. Green, 2014 .

Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study

S. Jagannath, A. Jakubowiak, S. Lonial, 2011 .

PX-171-003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis.

S. Jagannath, A. Jakubowiak, S. Lonial, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM)

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .

Clinical significance of clonal hematopoiesis in the setting of autologous stem cell transplantation for lymphoma

Trevor J Pugh, R. Kridel, J. Dick, 2022, American journal of hematology.

Very late relapse in Hodgkin lymphoma: Characterizing an understudied population.

R. Kridel, A. Prica, V. Kukreti, 2023, Clinical lymphoma, myeloma & leukemia.

Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1.

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012 .

Fixed duration vs. prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis

S. Trudel, D. Reece, Xuan Li, 2021, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

The impact of CD34+ cell collection yields for autologous transplant  on survival outcomes in multiple myeloma  

S. Trudel, D. Reece, K. Lajkosz, 2023, Clinical Lymphoma Myeloma and Leukemia.

Lenalidomide (Revlimid), Bortezomib (Velcade) and Dexamethasone (RVD) For The Treatment Of Secondary Plasma Cell Leukaemia

S. Trudel, D. Reece, V. Kukreti, 2013 .

Evaluation of Lymphadenopathy and Suspected Lymphoma in a Lymphoma Rapid Diagnosis Clinic.

R. Kridel, J. Delabie, M. Maganti, 2019, Journal of oncology practice.

A Phase II Trial of Myeloma Induction Therapy with Cyclophosphamide, Bortezomib, and Dexamethasone (Cybor-D): Improved Response over Historical Lenalidomide-Dexamethasone Controls.

P. L. Bergsagel, R. Fonseca, S. Trudel, 2007 .

A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.

Huyuan Yang, A. Hui, D. Seldin, 2017, Blood.

Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents

S. Trudel, R. Tsang, D. Reece, 2013, British journal of haematology.

Carfilzomib: High Single Agent Response Rate with Minimal Neuropathy Even In High-Risk Patients

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .